Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 7/20 | 1.00 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.85 |
| ▸ | CALCR | P30988 | 1/20 | 0.85 |
| ▸ | CALCA | P06881 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13599216 | 1.00 | CALCRL (1.00) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13599407 | 1.00 | CALCRL (1.00) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13599199 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13599202 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13599406 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL6344413 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13599198 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL13993499 | 0.99 | CALCRL (0.99) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL6345471 | 0.92 | CALCRL (0.85) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL6344216 | 0.92 | CALCRL (1.00) | CALCRLRAMP1RAMP3CALCRCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | CALCRL, CALCR, GRPR | CALCRL 1/4885RAMP1 54/4885RAMP3 23/4885 |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | CALCRL 2/4885RAMP1 75/4885RAMP3 95/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | CALCRL 2/4885RAMP1 70/4885RAMP3 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.